- Home
- LZ vs NVCR Comparison
LZ vs NVCR Comparison
Compare LZ & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | NVCR |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LZ | NVCR |
|---|---|---|
| Price | $6.55 | $12.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $9.79 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $756,043,000.00 | $655,353,000.00 |
| Revenue This Year | $11.50 | $7.72 |
| Revenue Next Year | $7.11 | $6.74 |
| P/E Ratio | $81.19 | ★ N/A |
| Revenue Growth | ★ 10.88 | 8.28 |
| 52 Week Low | $5.28 | $9.82 |
| 52 Week High | $12.40 | $20.05 |
Technical Indicators
Market Signals| Indicator | LZ | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 60.84 |
| Support Level | $5.36 | $12.66 |
| Resistance Level | $7.23 | $13.34 |
| Average True Range (ATR) | 0.29 | 0.54 |
| MACD | 0.14 | 0.29 |
| Stochastic Oscillator | 96.21 | 84.84 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.